Marishka DeToy

Marishka DeToy is a partner in Goodwin’s Life Sciences group and a member of the Capital Markets practice.

Marishka has a broad capital markets practice representing issuers and investment banks in a range of transactions, including initial public offerings, follow-on public offerings, registered direct offerings, ATMs and PIPEs. She also represents public companies in ongoing corporate matters, including SEC compliance and corporate governance.

Marishka’s experience includes, among others, representation of:

• IDRx, Inc. in its acquisition by GSK plc for $1 billion
• IDRx, Inc. in its $120 million Series B financing
• Prime Medicine, Inc. in its $175 million initial public offering and $161 million follow-on offering
• CRISPR Therapeutics AG in its $280 million registered direct offering
• Amylyx Pharmaceuticals, Inc. in its $60.0 million follow-on offering
• BeiGene in its $3.5 billion initial public offering on STAR Market of the Shanghai Stock Exchange in China
• BeiGene in its $2.08 billion registered direct offering and $340 million follow-on offering
• Black Diamond Therapeutics, Inc. in its $85 million Series C financing, $231.3 million initial public offering and $75 million follow-on offering
• Avadel Pharmaceuticals plc in its $65 million financing transaction, $125 million follow-on offering, $125 million follow-on offering and $75 million synthetic royalty financing
• The underwriters in Vera Therapeutics’ $287.5 million follow-on offering and $300.0 million follow-on offering
• The underwriters in Myriad Genetics’ $110 million follow-on offering
• The underwriters in VSE Corporation’s $112.7 million follow-on offering
• Theseus Pharmaceuticals, Inc. in its definitive acquisition by Concentra Biosciences, LLC
• Alkermes Pharmaceuticals plc in the spin-off of its oncology business into Mural Oncology
• BioDelivery Sciences International in its definitive acquisition by Collegium Pharmaceutical for $604 million
• Barinthus Biotherapeutics (formerly Vaccitech) plc in its $40 million acquisition of Avidea Technologies
• The underwriters in Alphatec’s $316.2 million convertible note offering
• The underwriters in Omega Therapeutics’ $125.8 million initial public offering
• Monte Rosa Therapeutics in its $222.3 million initial public offering
• Barinthus Biotherapeutics (formerly Vaccitech) plc in its $168 million Series B financing and $110 million initial public offering
• argenx NV in its $557 million and $1.15 billion follow-on offerings
• Goldman Sachs as lead underwriter in Taysha Gene Therapies, Inc.’s $181 million initial public offering
• The underwriters in Evelo Biosciences’ $72.6 million follow-on offering
• Fusion Pharmaceuticals Inc. in its $212.5 million initial public offering
• The underwriters in SQZ Biotechnologies Company’s $70 million initial public offering and $60 million follow-on offering
• scPharmaceuticals in its $50 million follow-on offering
• BeiGene in its $2.7 billion global strategic collaboration with Amgen
• Celyad SA in its $20 million follow-on offering and $32.5 million private placement
• Bicycle Therapeutics in its $60 million initial public offering
• BioDelivery Sciences International in its $60 million follow-on offering
• Kaleido Biosciences in its $75 million initial public offering
• Aerpio Pharmaceuticals in its $45 million follow-on offering

Marishka has been recognized as a “Next Generation Partner” in The Legal 500 2023-2024 in the Healthcare: Life Sciences category.

• Speaker, lSX Europe IPO Bootcamp, April 2025
• Speaker, IPO Launchpad Panel, London, UK, November 2024
• Panelist, CFGI Capital Markets Roundtable, September 2024
• Speaker, lSX Euopre IPO Bootcamp, April 2024
• IPO Bootcamp, London, UK, November 2023
• “Guide to the Initial Public Offering” publication in conjunction with toppan merrill, Fall 2023